Table 2 Demographic and clinical characteristics among all 5 phenotypes and in the “Non-classified” group
Characteristics n (wt%) | AwObesity n = 339 | B-Eos-high n = 237 | B-Eos&FeNO-low n = 157 | FeNO-high n = 110 | AwCOPD n = 57 | Non-classified†† n = 77 |
|---|---|---|---|---|---|---|
Female gender | 366 (67) | 196 (55) | 138 (78) | 78 (52) | 71 (58) | 44 (56) |
Age (yrs), median (Q1–Q3) | 48.0 (34.0–59.0) | 47.0 (31.0–59.0) | 41.0 (27.0–57.0) | 45.0 (30.0–54.0) | 61.0 (52.0–69.0) | 39.0 (28.0–53.0) |
BMI (kg/m2), median (Q1–Q3) | 35.4 (32.5–40.4) | 30.3 (25.9–36.8) | 28.9 (24.2–33.0) | 27.6 (24.9–33.4) | 30.3 (25.1–35.1) | 24.3 (22.8–27.5) |
Race and/or ethnicity | ||||||
Hispanic | 94 (9) | 78 (11) | 30 (8) | 29 (10) | 18 (4) | 11 (6) |
Non-Hispanic white | 230 (65) | 175 (73) | 79 (69) | 65 (75) | 80 (81) | 50 (86) |
Non-Hispanic black | 177 (21) | 74 (12) | 62 (17) | 38 (13) | 27 (11) | 10 (6) |
Other race | 25 (5) | 21 (4) | 13 (6) | 6 (2) | 10 (4) | 6 (2) |
Smoking status | ||||||
Current smoker | 150 (27) | 104 (32) | 48 (23) | 18 (13) | 65 (52) | 23 (28) |
Ex-smoker | 134 (27) | 100 (32) | 35 (25) | 42 (39) | 70 (48) | 18 (30) |
Non-smoker | 229 (45) | 124 (35) | 88 (51) | 66 (49) | 0 (0) | 36 (42) |
Education | ||||||
≥ High school | 358 (79) | 227 (80) | 125 (81) | 102 (87) | 73 (59) | 64 (91) |
Asthma-related medication‡ | ||||||
Reliever medication** | 234 (42) | 172 (51) | 82 (44) | 65 (46) | 69 (57) | 31 (36) |
Oral corticosteroids | 36 (5) | 17 (5) | 4 (2) | 10 (7) | 15 (7) | 2 (2) |
Inhaled corticosteroids§ | 144 (27) | 103 (32) | 36 (20) | 36 (33) | 60 (47) | 17 (19) |
Asthma-related outcomes | ||||||
Asthma attack | 363 (68) | 252 (74) | 125 (68) | 98 (71) | 85 (63) | 54 (75) |
Asthma-related ED | 130 (27) | 80 (23) | 41 (23) | 26 (13) | 37 (32) | 9 (8) |
> 2 asthma symptoms | 311 (66) | 199 (65) | 92 (55) | 80 (57) | 90 (74) | 42 (59) |
Work/school absenteeism | 66 (18) | 43 (16) | 25 (18) | 23 (14) | 12 (20) | 10 (14) |
Lung function | ||||||
FEV1% predicted, median (Q1–Q3) | 89.0 (75.6–99.2) | 84.1 (75.2–95.4) | 93.2 (83.8–100.8) | 82.7 (75.9–95.4) | 74.0 (62.9–90.1) | 89.9 (80.5–103.5) |
FEV1/FVC, median (Q1–Q3) | 0.77 (0.62–0.82) | 0.74 (0.65–0.80) | 0.79 (0.72–0.83) | 0.72 (0.66–0.79) | 0.63 (0.50–0.75) | 0.76 (0.69–0.82) |